{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:40:14Z","timestamp":1765546814491},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"7-8","license":[{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Hepatitis B is a potentially deadly infection that can be acquired by exposure to infectious human blood or body fluids. While service members and others at occupational risk are routinely vaccinated to prevent hepatitis B, non-responders to this vaccine are at continued risk. Heplisav-B is a newer vaccine that may offer additional protection to those at risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Cases of hepatitis B vaccine non-responders who were given Heplisav-B after receiving six or more doses of standard hepatitis B vaccine were collected from existing health records within the military health system after Uniformed Services University of the Health Sciences Institutional Review Board review.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twelve of thirteen (92%) prior non-responders who were tested at least 1\u00a0month after completing the recombinant Heplisav-B vaccine series demonstrated seroprotection against hepatitis B.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Ideally, all service members and other at-risk workers should be protected from hepatitis B. This case series suggests that prior non-responders are likely to gain protection from hepatitis B with Heplisav-B vaccination. A prospective trial is warranted for further evaluation of this potential indication.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/milmed\/usab397","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T07:52:25Z","timestamp":1632469945000},"page":"e811-e813","source":"Crossref","is-referenced-by-count":6,"title":["Heplisav-B in Prior Hepatitis B Vaccine Nonresponders: A Case Series"],"prefix":"10.1093","volume":"187","author":[{"given":"Alan l","family":"Williams","sequence":"first","affiliation":[{"name":"Department of Family Medicine, Uniformed Services University of the Health Sciences, University Occupational Health Service , Bethesda, MD 20184, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"key":"2022070112171756600_R1","article-title":"Hepatitis surveillance in the United States","author":"CDC","year":"2017"},{"key":"2022070112171756600_R2","article-title":"1910.1030 - bloodborne pathogens","author":"Occupational Safety and Health Administration"},{"issue":"2","key":"2022070112171756600_R3","first-page":"93","article-title":"Management approaches to Hepatitis B virus vaccination nonresponse","volume":"15","author":"Yanny","year":"2019","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"RR-7","key":"2022070112171756600_R4","first-page":"1","article-title":"Immunization of health\u2013care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","author":"Advisory Committee on Immunization Practices and Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Recomm Rep"},{"issue":"4","key":"2022070112171756600_R5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/(SICI)1096-9071(199612)50:4<283::AID-JMV1>3.0.CO;2-4","article-title":"Nonresponse to Hepatitis B vaccines and the kinetics of Anti-HBs production","volume":"50","author":"Zuckerman","year":"1996","journal-title":"J Med Virol"},{"issue":"15","key":"2022070112171756600_R6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.15585\/mmwr.mm6715a5","article-title":"Recommendations of the advisory committee on immunization practices for use of a Hepatitis B vaccine with a novel adjuvant","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022070112171756600_R7","author":"List of SOC Occupations"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/187\/7-8\/e811\/44369977\/usab397.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/187\/7-8\/e811\/44369977\/usab397.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T12:18:12Z","timestamp":1656677892000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/article\/187\/7-8\/e811\/6374755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":7,"journal-issue":{"issue":"7-8","published-online":{"date-parts":[[2021,9,24]]},"published-print":{"date-parts":[[2022,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/milmed\/usab397","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"value":"0026-4075","type":"print"},{"value":"1930-613X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2021,9,24]]}}}